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Abstract
The involvement of steroid hormones in breast carcinogenesis is well established. Recent evidence 
suggests that angiogenesis can be regulated by hormones. Both oestrogen and progesterone have 
been implicated in the angiogenic process of hormone-dependent cancers, such as breast cancer. 
Vascular Endothelial Growth Factor (VEGF) is a growth factor involved in angiogenesis in breast 
cancer that is up-regulated by estrogens. In our study we evaluated the role of progesterone in the 
expression of this angiogenic growth factor commonly up-regulated in breast cancer. Our findings 
indicate that progesterone activates an angiogenic pathway involving VEGF stimulation. The 
elucidation of specific angiogenic pathways promoted by progesterone can raise new therapeutic 
targets at least in a subset of breast cancers responsive to progesterone.
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Our group has been involved in the study of breast carcinogenesis [1]. Angiogenesis, the 
formation of new blood vessels from pre-existing ones, encompasses a complex multistep 
process involving extracellular matrix degradation, endothelial cell proliferation, migration, 
differentiation, alignment of migrating cell for tubular formation and anastomosis [2,3]. 
Active angiogenesis is required for pathologic processes such as inflammation and tumour 
growth. At exception is the female reproductive organs, in which angiogenesis is essential 
for tissue cyclic remodelling, occurring under the control of oestrogen and progesterone. 
Steroid hormones are known to play key roles in breast cancer [4] and several studies 
suggest that both oestrogen and progesterone might be involved in angiogenesis [5,6,7,8]. 
One of the genes that is up-regulated by oestrogen-Estrogen Receptor complex is Vascular 
Endothelial Growth Factor (VEGF) [9]. VEGF is directly involved in angiogenesis since it 
induces endothelial cell proliferation and permeability and is up-regulated in several tumour 
Correspondence to: Mónica C. Botelho, PhD, INSA - National Institute of Health Dr. Ricardo Jorge, Rua Alexandre Herculano, 321, 
4000-055, Porto, Portugal, Tel.: +351 223 401 114; fax: +351 223 401 109, monicabotelho@hotmail.com; monica.botelho@insa.min-
saude.pt. 
HHS Public Access
Author manuscript
SM J Reprod Health Infertil. Author manuscript; available in PMC 2015 December 02.
Published in final edited form as:
SM J Reprod Health Infertil. 2015 ; 1(1): .
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
types [10]. Although different stimuli have been described to induce VEGF expression and 
activity, there are few reports on the involvement of progesterone in VEGF expression. 
Hyder SM et al reported that progesterone stimulated the expression of VEGF in T47D 
human breast cancer cell line [8]. Chennazhi KP and Nayak NR on the other hand, have 
observed an upregulation of VEGFR1 with progesterone withdrawal in stromal cells of the 
endometrium, implying that progesterone might down-regulate VEGF signalling pathway in 
endometrial stromal cells [11]. Studying progesterone modulators in endometrial fibroblasts 
and epithelial cells, Classen-Linke I et al observed that the pharmacological effects of these 
agents could be cell specific [6]. VEGF overexpression has been reported in several 
angiogenic-dependent processes, such as psoriasis and wound healing [12]. Altogether these 
data suggest that progesterone might play a relevant role in angiogenesis, though, the exact 
pathway is still unknown.
Steroid hormones are known to regulate the expression of growth factors and growth factor 
receptors in breast cancer. Angiogenesis, on the other hand, is a complex multistep pathway 
that requires the presence of several cytokines and growth factors [3]. Several growth factors 
playing roles in angiogenesis have been shown to be activated by estrogens [2,3,9]. 
However, little is known regarding the implication of progesterone in angiogenesis. Our 
group has previously shown that platelet-derived growth factor (PDGF)-A is one of the 
progesterone target genes on breast cancer MCF7 and T47D cells [7]. Tumor-secreted 
PDGF-A is known to result in VEGF-producing fibroblast recruitment [13], reinforcing the 
complex interaction between tumor cells and distinct host cells through growth factors. 
Therefore, we focused our work on VEGF, an angiogenic growth factor that is strongly 
implicated in breast carcinogenesis. VEGF is a potent angiogenic factor, frequently 
overexpressed in tumour cells. It binds to one of three VEGF receptors (VEGFR1, 
VEGFR2, VEGFR3) which exhibit tyrosine kinase activity, thus activating a signalling 
transduction pathway involved in migration, proliferation and survival of endothelial cells 
(EC) [14]. Although VEGF pathway was primarily identified in EC, increasing evidence 
indicates that VEGF can be acting in tumour cells as well [10]. The presence of VEGF 
receptors have been identified in several tumour cells [15]. Four different isoforms have 
been described in tumours by alternative splicing of VEGF gene: VEGF121, VEGF165, 
VEGF189, VEGF206. The former two isoforms are efficiently secreted and stimulate cell 
proliferation. In contrast, the latter two isoforms (189 and 206) are generally cell-associated 
and linked to vascular permeability [16]. Therefore, VEGF can either be involved in 
paracrine or in autocrine pathways. In our study MCF7 cell culture expressed predominantly 
VEGF121 isoform, after progesterone stimulation, indicating a paracrine pathway for this 
secreted growth factor. Accordingly, other studies [15] showed that VEGF 121 isoform is 
the most frequently produced by tumour cells and is required for the initial stages of 
tumourigenesis. Our findings that progesterone potentiates VEGF 121 expression in MCF7 
cells suggest that this hormone is likely to be involved in the early stages of tumourigenesis.
Our results illustrate the role of progesterone in angiogenesis, through the activation of 
VEGF expression. Angiogenesis is a very complex process, involving several independent 
pathways. It is likely that many stimulus can lead to the activation of VEGF by different 
pathways.
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In conclusion, this study provides further evidence that progesterone is mediating 
tumorigenesis in breast cancer, emphasising the role of this hormone in promoting the 
angiogenic phenotype. Clarifying the role of progesterone in angiogenesis might be useful to 
define new therapeutic strategies, at least for a specific subset of tumours that respond to 
progesterone.
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